VNDA - Vanda Pharmaceuticals Inc Stock Price, Fair Value and News

$4.78+0.15 (+3.24%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

VNDA Price Action

Last 7 days

3.7%

Last 30 days

-2.4%

Last 90 days

3.7%

Trailing 12 Months

24.2%

VNDA RSI Chart

VNDA Valuation

Market Cap

278.7M

Price/Earnings (Trailing)

-17.01

Price/Sales (Trailing)

1.46

EV/EBITDA

-10.34

Price/Free Cashflow

-15.31

VNDA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

VNDA Fundamentals

VNDA Revenue

Revenue (TTM)

190.9M

Rev. Growth (Yr)

22.76%

Rev. Growth (Qtr)

-5.59%

VNDA Earnings

Earnings (TTM)

-16.4M

Earnings Growth (Yr)

-4.0K%

Earnings Growth (Qtr)

-17.84%

VNDA Profitability

EBT Margin

-9.48%

Return on Equity

-3.03%

Return on Assets

-2.54%

Free Cashflow Yield

-6.53%

VNDA Investor Care

Shares Dilution (1Y)

1.35%

Diluted EPS (TTM)

-0.29

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	177.6M	182.0M	190.9M	0
2023	256.7M	238.4M	211.9M	192.6M
2022	266.2M	262.7M	257.9M	254.4M
2021	252.8M	258.5M	268.3M	268.7M
2020	237.5M	240.6M	241.4M	248.2M
2019	197.2M	208.9M	219.3M	227.2M
2018	171.3M	176.6M	184.4M	193.1M
2017	150.2M	156.2M	159.1M	165.1M
2016	121.0M	129.5M	139.6M	146.0M
2015	49.2M	75.2M	98.2M	109.9M
2014	33.3M	26.5M	23.1M	34.5M
2013	32.7M	32.6M	33.0M	33.9M
2012	31.9M	32.9M	33.2M	32.7M
2011	30.8M	29.9M	30.7M	31.3M
2010	0	14.9M	25.3M	35.7M
2009	0	0	0	4.5M

Get all data in R, Python etc through our Historical Stock Data APIs

About Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

CEO	Dr. Mihael H. Polymeropoulos M.D.
WEBSITE	vandapharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	290

Vanda Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Vanda Pharmaceuticals Inc? What does VNDA stand for in stocks?

VNDA is the stock ticker symbol of Vanda Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vanda Pharmaceuticals Inc (VNDA)?

As of Fri Dec 20 2024, market cap of Vanda Pharmaceuticals Inc is 278.71 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VNDA stock?

You can check VNDA's fair value in chart for subscribers.

Is Vanda Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether VNDA is over valued or under valued. Whether Vanda Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Vanda Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VNDA.

What is Vanda Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, VNDA's PE ratio (Price to Earnings) is -17.01 and Price to Sales (PS) ratio is 1.46. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VNDA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Vanda Pharmaceuticals Inc's stock?

In the past 10 years, Vanda Pharmaceuticals Inc has provided -0.099 (multiply by 100 for percentage) rate of return.